Frontier Medicines and LG Chem Forge Strategic Global Partnership for First-in-Class p53 Y220C Activator FMC-220 Frontier Medicines Corporation has entered into a landmark exclusive licensing agreement with LG Chem, Ltd. for its novel oncology candidate FMC-220, a first-in-class covalent activator…
Mosaic Therapeutics Strengthens Leadership with Appointment of Dr. Vince O’Neill as Head of R&D Mosaic Therapeutics, a clinical-stage oncology company focused on developing next-generation combination therapies, has announced the appointment of Dr. Vince O’Neill, MD, as its new Head of…
ENDRA Life Sciences Reports 2025 Financial Results and Highlights Strategic Progress ENDRA Life Sciences Inc a company focused on advancing thermoacoustic biomarker imaging technology, has announced its financial results for the fourth quarter and full year ended December 31, 2025.…
Healthy Smiles Never Gets Old 2.0: Advancing Oral Health for California’s Aging Population The Center for Oral Health has released Healthy Smiles Never Gets Old 2.0, a comprehensive updated report that examines the oral health status, challenges, and opportunities facing…
AHF Honors Stephen Lewis’ Global Health Legacy AIDS Healthcare Foundation (AHF) has paid tribute to the life and legacy of Stephen Lewis, a towering figure in global health diplomacy and a relentless champion in the fight against HIV His passing…
Sub-Q Bionics Raises $1.5 Million Pre-Seed Round to Advance Breakthrough Lymphedema Technology Sub-Q Bionics, an emerging medical device company focused on transforming the treatment landscape for lymphedema, has successfully closed a $1.5 million pre-seed financing round. This milestone marks an…
Dante Labs Genome Report Helps Single Mother Identify Her Children’s Rare Disease and Find Specialist Care A Mother’s Search for Answers For years, Susan lived with a quiet but persistent fear—one that surfaced every time her children suddenly collapsed without…
Scholar Rock Resubmits BLA for Apitegromab in SMA Treatment Scholar Rock has announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab, an investigational therapy intended for the treatment of children…
AN2 Therapeutics Initiates Phase 2 Trial of Epetraborole for Difficult-to-Treat M. abscessus Lung Disease AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies using its proprietary boron chemistry platform, has announced the initiation of a…
Emerging biotech advances novel platform to target previously “undruggable” epigenetic protein interfaces, aiming to develop precision therapies for pediatric brain cancers like DIPG TippingPoint Biosciences, an emerging player in the biotechnology sector, is positioning itself at the forefront of next-generation…
New ACC.26 Data Strengthen Evidence for Vutrisiran in ATTR-CM and Highlight Zilebesiran’s Potential in Hypertension Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, announced new clinical and real-world findings from its cardiovascular portfolio at the American College of Cardiology’s…
PepGen Reports Positive Topline Results from Lowest-Dose (5 mg/kg) MAD Cohort in Phase 2 FREEDOM2 Study, Highlighting Safety, Splicing, and vHOT Outcomes PepGen has reported encouraging topline results from the lowest-dose cohort (5 mg/kg) in its ongoing Phase 2 FREEDOM2…